GRAIL went public through mergers and acquisitions（M&A), making the number of SCGC's listing cases increased to 197
October 08, 2021
In August 2021, GRAIL, Inc. (hereinafter referred to as "GRAIL"), the world's leading early cancer screening company announced that it had reached an agreement with Illumina Inc. (NASDAQ: ILMN), the world's largest supplier of gene sequencing equipment, which then helped GRAIL go public through M&A with cash and stocks of US $8 billion. GRAIL was the 197th company invested by SCGC that went public and the 17th listing case of SCGC in 2021.
In 2017, the wholly-owned overseas subsidiary of SCGC and the overseas parallel fund West Fountain Global Fund LP jointly completed the B+ round of investment in GRAIL. In 2020, West Fountain participated in GRAIL's D round investment.
